Our company

iTeos was founded in 2011 as a spin off of the Ludwig Cancer Research (LICR) and de Duve Institute at University of Louvain (UCL). iTeos started its operation in 2012 by building its research insights based upon the unparalleled expertise of the LICR, a world-class Research Institute in the fields of tumor immunology, therapeutic cancer vaccines, cancer biology and translational medicine in cancer.

Located in Gosselies, Belgium and funded by a unique mix of private investors and public money, iTeos has attracted academic partners eager to explore the therapeutic application of their cutting-edge research and business partners with a proven track record of success and unparalleled expertise in tumor immunology, cancer immunotherapy and drug discovery. iTeos is strategically positioned to deliver the next generation of cancer immunotherapies.